Corticosteróides inalados no tratamento da alergia respiratória: segurança versus eficácia

Detalhes bibliográficos
Autor(a) principal: Rizzo, Maria Cândida V. [UNIFESP]
Data de Publicação: 2006
Outros Autores: Solé, Dirceu [UNIFESP]
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://dx.doi.org/10.1590/S0021-75572006000700010
http://repositorio.unifesp.br/handle/11600/3336
Resumo: OBJECTIVE: Review the molecular mechanisms of action, efficacy, and potential side effects associated with inhaled corticosteroids (ICS) in children with persistent asthma. SOURCES: Articles in English from MEDLINE. The following terms were used: corticosteroids, inhaled corticosteroids, asthma, children, beclomethasone, fluticasone, budesonide, ciclesonide, growth, adrenal insufficiency, bone mineral density, and oral candidiasis. Treatment guidelines, review articles, controlled trials, meta-analyses, and systematic reviews evaluating the efficacy and the adverse events of treatment with ICS were selected. SUMMARY OF THE FINDINGS: In vivo and in vitro studies show that the available ICS have different pharmacokinetic and pharmacodynamic properties that result in different action potentials. ICS also differ as to the systemic and local side effects. The bioavailability of these products is essential in order to determine the incidence of side effects. In general, ICS are capable of controlling asthma, reducing the number of exacerbations, medical consultations, hospitalizations, and the need of oral corticosteroid (applications) bursts. Improvement can also be seen in pulmonary function, especially in patients with recent onset asthma. The most documented adverse effect is transitory decrease of growth rate. CONCLUSIONS: ICS are the main anti-inflammatory agent used to treat persistent asthma. When administered in low doses, they seem to be safe and effective. Patient monitoring allows for early detection of possible side effects associated with ICS.
id UFSP_1e25c002e09e0e1625f366aa0bf8acc2
oai_identifier_str oai:repositorio.unifesp.br/:11600/3336
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Corticosteróides inalados no tratamento da alergia respiratória: segurança versus eficáciaInhaled corticosteroids in the treatment of respiratory allergy: safety vs. efficacyChildrenasthmainhaled corticosteroidsbudesonidebeclomethasonefluticasoneciclesonideCriançaasmacorticosteróides inaladosbudesonidabeclometasonafluticasonaciclenonidaOBJECTIVE: Review the molecular mechanisms of action, efficacy, and potential side effects associated with inhaled corticosteroids (ICS) in children with persistent asthma. SOURCES: Articles in English from MEDLINE. The following terms were used: corticosteroids, inhaled corticosteroids, asthma, children, beclomethasone, fluticasone, budesonide, ciclesonide, growth, adrenal insufficiency, bone mineral density, and oral candidiasis. Treatment guidelines, review articles, controlled trials, meta-analyses, and systematic reviews evaluating the efficacy and the adverse events of treatment with ICS were selected. SUMMARY OF THE FINDINGS: In vivo and in vitro studies show that the available ICS have different pharmacokinetic and pharmacodynamic properties that result in different action potentials. ICS also differ as to the systemic and local side effects. The bioavailability of these products is essential in order to determine the incidence of side effects. In general, ICS are capable of controlling asthma, reducing the number of exacerbations, medical consultations, hospitalizations, and the need of oral corticosteroid (applications) bursts. Improvement can also be seen in pulmonary function, especially in patients with recent onset asthma. The most documented adverse effect is transitory decrease of growth rate. CONCLUSIONS: ICS are the main anti-inflammatory agent used to treat persistent asthma. When administered in low doses, they seem to be safe and effective. Patient monitoring allows for early detection of possible side effects associated with ICS.OBJETIVO: Revisar os mecanismos moleculares de ação, eficácia e potenciais efeitos adversos relacionados aos corticosteróides inalados (CEI) em crianças com asma persistente. FONTES DOS DADOS: Artigos de língua inglesa da base de dados MEDLINE. Foram empregados os termos: corticosteroids, inhaled corticosteroids, asthma, children, beclomethasone, fluticasone, budesonide, ciclesonide, growth, adrenal insufficiency, bone mineral density, oral candidiasis. Foram selecionados guias de tratamento, artigos de revisão, estudos controlados, meta-análises e revisões sistemáticas que avaliaram a eficácia e os eventos adversos do tratamento com CEI. SÍNTESE DOS DADOS: Estudos in vivo e in vitro mostram que os CEI disponíveis apresentam diferentes características farmacocinéticas e farmacodinâmicas que lhes conferem diferentes potenciais de ação. Os CEI também diferem quanto aos efeitos adversos sistêmicos e locais. Salienta-se a biodisponibilidade desses produtos como essencial para determinar a incidência de efeitos colaterais. Em linhas gerais, os CEI são capazes de controlar a asma, reduzindo o número de exacerbações, atendimentos médicos, hospitalizações e a necessidade de pulsos de corticosteróides orais. Também se observa melhora da função pulmonar, sobretudo nos pacientes com asma de início recente. O efeito adversos mais documentado é a desaceleração transitória do ritmo de crescimento. CONCLUSÕES: Os CEI são o principal agente antiinflamatório utilizado no tratamento da asma persistente. Quando administrados em doses baixas, mostram-se seguros e efetivos. O monitoramento dos pacientes permite a detecção precoce de eventuais efeitos adversos associados aos CEI.Universidade Federal de São Paulo (UNIFESP) Escola Paulista de Medicina Departamento de PediatriaUNIFESP, EPM, Depto. de PediatriaSciELOSociedade Brasileira de PediatriaUniversidade Federal de São Paulo (UNIFESP)Rizzo, Maria Cândida V. [UNIFESP]Solé, Dirceu [UNIFESP]2015-06-14T13:36:31Z2015-06-14T13:36:31Z2006-11-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionS198-S205application/pdfhttp://dx.doi.org/10.1590/S0021-75572006000700010Jornal de Pediatria. Sociedade Brasileira de Pediatria, v. 82, n. 5, p. S198-S205, 2006.10.1590/S0021-75572006000700010S0021-75572006000700010.pdf0021-7557S0021-75572006000700010http://repositorio.unifesp.br/handle/11600/3336porJornal de Pediatriainfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-07-28T11:47:24Zoai:repositorio.unifesp.br/:11600/3336Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-07-28T11:47:24Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Corticosteróides inalados no tratamento da alergia respiratória: segurança versus eficácia
Inhaled corticosteroids in the treatment of respiratory allergy: safety vs. efficacy
title Corticosteróides inalados no tratamento da alergia respiratória: segurança versus eficácia
spellingShingle Corticosteróides inalados no tratamento da alergia respiratória: segurança versus eficácia
Rizzo, Maria Cândida V. [UNIFESP]
Children
asthma
inhaled corticosteroids
budesonide
beclomethasone
fluticasone
ciclesonide
Criança
asma
corticosteróides inalados
budesonida
beclometasona
fluticasona
ciclenonida
title_short Corticosteróides inalados no tratamento da alergia respiratória: segurança versus eficácia
title_full Corticosteróides inalados no tratamento da alergia respiratória: segurança versus eficácia
title_fullStr Corticosteróides inalados no tratamento da alergia respiratória: segurança versus eficácia
title_full_unstemmed Corticosteróides inalados no tratamento da alergia respiratória: segurança versus eficácia
title_sort Corticosteróides inalados no tratamento da alergia respiratória: segurança versus eficácia
author Rizzo, Maria Cândida V. [UNIFESP]
author_facet Rizzo, Maria Cândida V. [UNIFESP]
Solé, Dirceu [UNIFESP]
author_role author
author2 Solé, Dirceu [UNIFESP]
author2_role author
dc.contributor.none.fl_str_mv Universidade Federal de São Paulo (UNIFESP)
dc.contributor.author.fl_str_mv Rizzo, Maria Cândida V. [UNIFESP]
Solé, Dirceu [UNIFESP]
dc.subject.por.fl_str_mv Children
asthma
inhaled corticosteroids
budesonide
beclomethasone
fluticasone
ciclesonide
Criança
asma
corticosteróides inalados
budesonida
beclometasona
fluticasona
ciclenonida
topic Children
asthma
inhaled corticosteroids
budesonide
beclomethasone
fluticasone
ciclesonide
Criança
asma
corticosteróides inalados
budesonida
beclometasona
fluticasona
ciclenonida
description OBJECTIVE: Review the molecular mechanisms of action, efficacy, and potential side effects associated with inhaled corticosteroids (ICS) in children with persistent asthma. SOURCES: Articles in English from MEDLINE. The following terms were used: corticosteroids, inhaled corticosteroids, asthma, children, beclomethasone, fluticasone, budesonide, ciclesonide, growth, adrenal insufficiency, bone mineral density, and oral candidiasis. Treatment guidelines, review articles, controlled trials, meta-analyses, and systematic reviews evaluating the efficacy and the adverse events of treatment with ICS were selected. SUMMARY OF THE FINDINGS: In vivo and in vitro studies show that the available ICS have different pharmacokinetic and pharmacodynamic properties that result in different action potentials. ICS also differ as to the systemic and local side effects. The bioavailability of these products is essential in order to determine the incidence of side effects. In general, ICS are capable of controlling asthma, reducing the number of exacerbations, medical consultations, hospitalizations, and the need of oral corticosteroid (applications) bursts. Improvement can also be seen in pulmonary function, especially in patients with recent onset asthma. The most documented adverse effect is transitory decrease of growth rate. CONCLUSIONS: ICS are the main anti-inflammatory agent used to treat persistent asthma. When administered in low doses, they seem to be safe and effective. Patient monitoring allows for early detection of possible side effects associated with ICS.
publishDate 2006
dc.date.none.fl_str_mv 2006-11-01
2015-06-14T13:36:31Z
2015-06-14T13:36:31Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1590/S0021-75572006000700010
Jornal de Pediatria. Sociedade Brasileira de Pediatria, v. 82, n. 5, p. S198-S205, 2006.
10.1590/S0021-75572006000700010
S0021-75572006000700010.pdf
0021-7557
S0021-75572006000700010
http://repositorio.unifesp.br/handle/11600/3336
url http://dx.doi.org/10.1590/S0021-75572006000700010
http://repositorio.unifesp.br/handle/11600/3336
identifier_str_mv Jornal de Pediatria. Sociedade Brasileira de Pediatria, v. 82, n. 5, p. S198-S205, 2006.
10.1590/S0021-75572006000700010
S0021-75572006000700010.pdf
0021-7557
S0021-75572006000700010
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv Jornal de Pediatria
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv S198-S205
application/pdf
dc.publisher.none.fl_str_mv Sociedade Brasileira de Pediatria
publisher.none.fl_str_mv Sociedade Brasileira de Pediatria
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268270670249984